[Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)].
OBJECTIVE
Comparison of two treatment regimens of eradication treatment of duodenal ulcer (DU) associated with Helicobacter pylori based on fromilid (clarithromycin).


METHODS
20 DU patients associated with HP were divided into two groups. 10 patients of group 1 received omeprazol, fromilid and metronidazol and 10 patients of group 2 were given omeprazol, fromilid and furasolidon for 7 days followed by 2-week omeprazol alone. The patients were examined clinically and endoscopically; HP were detected with a fast urease test and polymerase chain reaction before and after the treatment. Control examinations were performed 6 weeks after the medication.


RESULTS
In group 1 duodenal healing was observed in all the 10 patients, HP eradication occurred in 9 of 10 patients by urease test and in 4 patients by PCR, in group 2 in 8 of 10, 10 of 10 and 10 of 10, respectively.


CONCLUSIONS
Fromilid (clarithromycin) is effective in eradication treatment in combination with fromilid and metronidazol or furazolidon.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use; D016133:Polymerase Chain Reaction
D000900:Anti-Bacterial Agents; D008795:Metronidazole; D017291:Clarithromycin; D009853:Omeprazole
Fromilid (klaritromitsin) v éradikatsionnoĭ terapii bol'nykh iazvennoĭ bolezn'iu dvenadtsatiperstnoĭ kishki, assotsiirovannoĭ s Helicobacter pylori (rezul'taty sopostavleniia dvukh variantov lecheniia).